Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.43 |
| ▸ | NPY1R | P25929 | 9/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305283 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL30658141 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30302888 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL29799967 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL29732279 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL30302954 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL30148469 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL31110537 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL30945395 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL30582104 | 0.93 | FURIN (0.42) | NPY4RNPY1RNPY5RNPY2RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119318716-A | Folic acid-polylactic acid double-layer vesicle delivery system for targeting MDSC cells in focus, and preparation method and application thereof | 中山大学附属第一医院 | 2025-01-17 | — | — | CN | claimed |
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-119286742-B | Lactobacillus delbrueckii subspecies lactis YN-01, products prepared from same and application thereof | 内蒙古农业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119286742-A | Lactobacillus delbrueckii subspecies lactis YN-01, products prepared from same and application thereof | 内蒙古农业大学 | 2025-01-10 | — | — | CN | disclosed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | NPY4R 2434/4885NPY1R 2661/4885NPY5R 2862/4885 |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | NPY4R 3117/4885NPY1R 2841/4885NPY5R 3210/4885 |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | NPY4R 2434/4885NPY1R 2661/4885NPY5R 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.